Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active Surveillance After Neoadjuvant Adebrelimab in ESCC
NCT06861894Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Countries
- 1
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- adebrelimab
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: 2-year Overall Survival Rate. Planned start Jul 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Perioperative Treatment
Adebrelimab + CRT followed by response-adapted management
03
Who it enrols
Patients with resectable thoracic esophageal squamous cell carcinoma (cII-III) who have not received prior anti-tumor treatment.
04
Endpoints
Primary
2-year Overall Survival Rate
Secondary
Clinical Complete Response Rate
Median Event-Free Survival
Median Overall Survival
Incidence, type and severity of adverse events
Quality of Life
Beyond the preview
Go deeper on NCT06861894.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861894.